AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Low Bone Mineral Density|Osteopenia
Interventions: DRUG: Placebo|DRUG: AMG 162 / Denosumab
Sponsor: Amgen